Furthermore, EGFR mRNA expression was found to be upregulated over 10-fold in the spinal cord of human ALS patients as well as in that of the SOD1G93A mouse model [16], suggesting that pharmacological inhibition of EGFR signaling could be a feasible strategy to slow progression of this disease. The gene discussed is EGFR; the disease is amyotrophic lateral sclerosis.